Brief: Biophytis To Meet With FDA To Advance Sarconeos Development In Sarcopenia From Phase 2 To Phase 3

Biophytis SA

16/12/2021 07:03

Dec 16 (Reuters) - Biophytis SA  ALBPS.PA :
    * BIOPHYTIS TO MEET WITH FDA TO ADVANCE SARCONEOS (BIO101)
DEVELOPMENT IN SARCOPENIA FROM PHASE 2 TO PHASE 3
    * FOLLOWING PHASE2B/SARA-INTEREST CLINICALLY MEANINGFUL
RESULTS,
BIOPHYTIS IS STARTING FIRST REGULATORY ACTIVITIES TO ADVANCE
FROM PHASE 2 TO PHASE 3 DEVELOPMENT
    * A TYPE B/END-OF-PHASE 2 MEETING IS PLANNED WITH FDA (FOOD
AND
DRUG ADMINISTRATION) ON JANUARY 24TH, 2022, TO DISCUSS THESE
RESULTS AND PHASE 3 PROTOCOL DESIGN
    * ASSUMING POTENTIAL AGREEMENT AND APPROVAL FROM US
AUTHORITIES
BIOPHYTIS INTENDS TO INITIATE ITS PHASE 3 PROGRAM IN SARCOPENIA
IN H2 2022

Source text for Eikon:  ID:nEQ3PnP7ja 
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))